Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

That reflects loss of exclusivity on AstraZeneca's top-selling cholesterol-lowering drug Crestor in 2016, as well as the coming hit from competition to Nexium, which is expected to have its ...

AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of generic copies of its Nexium drug in the United States kept cash flowing from the ...

After nearly 15 years on the market, AstraZeneca’s popular “purple pill,” Nexium, will face generic competition. Teva Pharmaceuticals, an Israeli generics manufacturer with American headquarters in ...

Shares in AstraZeneca jump nearly 11% after the drugmaker announces it has settled a patent infringement case with Ranbaxy Laboratories over its Nexium ulcer drug.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange ...

Drugs giant AstraZeneca has agreed to settle a raft of legal claims over its heartburn treatments for 425 million US dollars (£352 million).

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec ...

AstraZeneca will pay $425 million to settle lawsuits on behalf of consumers who suffered kidney injuries while using its heartburn medications Nexium and Prilosec.

AstraZeneca has agreed to pay $425 million to settle product liability suits over two heartburn drugs, Prilosec and Nexium.

Multinational pharmaceutical maker AstraZeneca said Tuesday it will pay $425 million to settle lawsuits from people who experienced kidney damage from the company's heartburn medications Nexium ...